BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AmpliPhi Biosciences (TGEN) to Present at Rodman & Renshaw Global Investment Conference in New York


9/7/2012 1:05:38 PM

RICHMOND, VA and LONDON, UK September 7, 2012 AmpliPhi Biosciences Corporation (APHB.PK), the leader in the development of bacteriophage-based anti-bacterial therapies to treat resistant bacterial infections, will present at this year’s Rodman & Renshaw Annual Global Investment Conference in New York.

The presentation will be given by CEO, Philip J. Young on Monday, September 10, 2012 at 4:05PM US Eastern Time, and will provide an update to the market on progress that Ampliphi has made in the last twelve months since its creation in 2011 through the merger of Biocontrol Ltd with Targeted Genetics Inc.

AmpliPhi Biosciences

AmpliPhi BioSciences Corporation [APHB.PK], created in 2011 through the merger of Biocontrol Limited with Targeted Genetics Inc., is a biotechnology company dedicated to the development of innovative antibacterial solutions to improve human health through the application of its proprietary bacteriophage platform. The Company’s lead product development programs are targeting Gram-negative infections that are often resistant to existing antibiotic treatments. For more information, please visit www.ampliphibio.com

For further information please contact:

At the Company:

Phil Young, CEO

pjy@ampliphibio.com

+1 650-888-2422


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->